Valneva SE announced that the United Arab Emirates (UAE) granted emergency use authorization for Valneva's inactivated, adjuvanted COVID-19 vaccine, VLA2001. This authorization follows Conditional Marketing Authorization from the UK MHRA1, which was granted last month, and emergency use authorization from the Bahraini NHRA in March 2022.
Market Closed -
Other stock markets
|
After market 13:27:13 | |||
3.418 EUR | -0.47% | 3.424 | +0.18% |
04-11 | Valneva: Deep Track Biotechnology Master holds less than 5% of the capital | CF |
03-26 | Valneva Kicks Off Early-stage Trial for Zika Vaccine Candidate | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.58% | 513M | |
+22.07% | 47.9B | |
+46.56% | 41.42B | |
-2.37% | 40.7B | |
-6.20% | 28.92B | |
+10.68% | 25.55B | |
-21.55% | 19.27B | |
-2.33% | 12.15B | |
+31.24% | 12.14B | |
-0.84% | 11.99B |
- Stock Market
- Equities
- VLA Stock
- News Valneva
- Valneva SE Receives Emergency Use Authorization from the United Arab Emirates for its Inactivated COVID-19 Vaccine